Search research articles
Contact Us
Filters
Showing results (211-220 of 461) with videos related to
Page
of 47
Sort By:
American Journal of Clinical Dermatology
|
September 8, 2019
Efficacy, Safety, and Patient-Reported Outcomes in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Brodalumab for 5 Years in a Long-Term, Open-Label, Phase II Study
Mark G Lebwohl, Andrew Blauvelt, Alan Menter, et al.
Journal of Medicinal Chemistry
|
February 1, 1982
A new stable prostacyclin mimic, 7-oxoprostaglandin I2
G Kovács, V Simonidesz, I Tömösközi, et al.
The British Journal of Dermatology
|
September 6, 2019
Efficacy and safety of tildrakizumab for plaque psoriasis with continuous dosing, treatment interruption, dose adjustments and switching from etanercept: results from phase III studies
A B Kimball, K A Papp, K Reich, et al.
Journal of Cutaneous Medicine and Surgery
|
February 23, 2018
OBSERVE-5: Comparison of Etanercept-Treated Psoriasis Patients From Canada and the United States
Kim A Papp, Marc Bourcier, Yves Poulin, et al.
Psychiatry Research
|
May 1, 1989
Prolactin and sodium lactate-induced panic
E Hollander, M R Liebowitz, B Cohen, et al.
The British Journal of Dermatology
|
June 24, 2006
CLinical experience acquired with the efalizumab (Raptiva) (CLEAR) trial in patients with moderate-to-severe plaque psoriasis: results from a phase III international randomized, placebo-controlled trial
L Dubertret, W Sterry, J D Bos, et al.
Journal of the American Academy of Dermatology
|
September 21, 2010
Assessment of the long-term safety and effectiveness of etanercept for the treatment of psoriasis in an adult population
Kim A Papp, Yves Poulin, Robert Bissonnette, et al.
The Journal of Dermatological Treatment
|
July 15, 2020
Continuous treatment with guselkumab maintains clinical responses through 4 years in patients with moderate-to-severe psoriasis: results from VOYAGE 1
Christopher E M Griffiths, Kim A Papp, Michael Song, et al.
Stem Cells Translational Medicine
|
July 8, 2025
Use of adipose-derived stem cells on decellularized bladder scaffolds for functional bladder mucosa regeneration
Cesar Ulises Monjaras-Avila, Ana Cecilia Luque-Badillo, Nicholas J Carr, et al.
Journal of the American Academy of Dermatology
|
July 21, 2015
Five-year analysis from the ESPRIT 10-year postmarketing surveillance registry of adalimumab treatment for moderate to severe psoriasis
Alan Menter, Diamant Thaçi, Kim A Papp, et al.
Page
of 47
Search research articles
Search
Showing results (211-220 of 461) with videos related to
Sort By:
Page
of 47
American Journal of Clinical Dermatology
|
September 8, 2019
Efficacy, Safety, and Patient-Reported Outcomes in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Brodalumab for 5 Years in a Long-Term, Open-Label, Phase II Study
Mark G Lebwohl, Andrew Blauvelt, Alan Menter, et al.
Journal of Medicinal Chemistry
|
February 1, 1982
A new stable prostacyclin mimic, 7-oxoprostaglandin I2
G Kovács, V Simonidesz, I Tömösközi, et al.
The British Journal of Dermatology
|
September 6, 2019
Efficacy and safety of tildrakizumab for plaque psoriasis with continuous dosing, treatment interruption, dose adjustments and switching from etanercept: results from phase III studies
A B Kimball, K A Papp, K Reich, et al.
Journal of Cutaneous Medicine and Surgery
|
February 23, 2018
OBSERVE-5: Comparison of Etanercept-Treated Psoriasis Patients From Canada and the United States
Kim A Papp, Marc Bourcier, Yves Poulin, et al.
Psychiatry Research
|
May 1, 1989
Prolactin and sodium lactate-induced panic
E Hollander, M R Liebowitz, B Cohen, et al.
The British Journal of Dermatology
|
June 24, 2006
CLinical experience acquired with the efalizumab (Raptiva) (CLEAR) trial in patients with moderate-to-severe plaque psoriasis: results from a phase III international randomized, placebo-controlled trial
L Dubertret, W Sterry, J D Bos, et al.
Journal of the American Academy of Dermatology
|
September 21, 2010
Assessment of the long-term safety and effectiveness of etanercept for the treatment of psoriasis in an adult population
Kim A Papp, Yves Poulin, Robert Bissonnette, et al.
The Journal of Dermatological Treatment
|
July 15, 2020
Continuous treatment with guselkumab maintains clinical responses through 4 years in patients with moderate-to-severe psoriasis: results from VOYAGE 1
Christopher E M Griffiths, Kim A Papp, Michael Song, et al.
Stem Cells Translational Medicine
|
July 8, 2025
Use of adipose-derived stem cells on decellularized bladder scaffolds for functional bladder mucosa regeneration
Cesar Ulises Monjaras-Avila, Ana Cecilia Luque-Badillo, Nicholas J Carr, et al.
Journal of the American Academy of Dermatology
|
July 21, 2015
Five-year analysis from the ESPRIT 10-year postmarketing surveillance registry of adalimumab treatment for moderate to severe psoriasis
Alan Menter, Diamant Thaçi, Kim A Papp, et al.
Page
of 47